

Annual Flash Report (unaudited)

Fiscal Year ended March 31, 2018

Sales of Major Products

Supplemental Data

		Hundreds of Millions of yen									
		Year ended March 31, 2018			Year ending March 31, 2019						
		Results		Increase/Decrease		Forecasts		Increase/Decrease			
Opdivo	Agent for cancer	¥	901	¥	Δ 138	Δ 13.3 %	¥	900	¥	Δ 1	Δ 0.1 %
Glactiv	Agent for type II diabetes		274		Δ 20	Δ 6.7 %		260		Δ 14	Δ 5.1 %
Orencia SC	Agent for rheumatoid arthritis		141		26	22.0 %		165		24	16.8 %
Forxiga	Agent for type II diabetes		111		33	41.8 %		130		19	17.4 %
Opalmon	Circulatory system agent		144		Δ 27	Δ 15.6 %		105		Δ 39	Δ 26.9 %
Emend/Proemend	Agent for Chemotherapy-induced nausea and vomiting		99		1	0.7 %		105		6	5.5 %
Recalbon	Agent for osteoporosis		109		Δ 4	Δ 3.3 %		95		Δ 14	Δ 13.0 %
Rivastach	Agent for Alzheimer's disease		89		0	0.3 %		90		1	1.3 %
Kyprolis	Agent for multiple myeloma		55		36	182.4 %		65		10	17.4 %
Parsabiv	Agent for secondary hyperparathyroidism		34		32	1660.3 %		55		21	60.4 %
Onon	Agent for bronchial asthma and allergic rhinitis		55		Δ 13	Δ 19.5 %		45		Δ 10	Δ 17.6 %
Onoact	Agent for tachyarrhythmia during and post operation		56		Δ 1	Δ 1.8 %		40		Δ 16	Δ 28.8 %
Staybla	Agent for overactive bladder		41		Δ 6	Δ 13.4 %		35		Δ 6	Δ 15.3 %
Onon dry syrup	Agent for pediatric bronchial asthma and allergic rhinitis		33		Δ 8	Δ 18.8 %		25		Δ 8	Δ 25.0 %

Note: Sales of products are shown in a gross sales basis.